GlassScriptPhysician profile
Mitchell Theodore Oei
NPI 1760111744
$1,226.29
in general payments reported to CMS, 2019-2025
21 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $38.78 · 2023: $303 · 2024: $546 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $550.56 | 2022-2025 | Briviact |
| Alexion Pharmaceuticals, INC. | $63.08 | 2024-2025 | Ultomiris |
| Biogen, INC. | $53.47 | 2025 | Spinraza, Skyclarys |
| Takeda Pharmaceuticals U.S.A., INC. | $52.86 | 2024-2025 | Hyqvia |
| Averitas Pharma INC. | $45.92 | 2025 | Qutenza |
| Sk Life Science, INC. | $45.20 | 2024 | |
| Abbvie INC. | $44.64 | 2025 | |
| Alnylam Pharmaceuticals INC. | $37.37 | 2024 | Amvuttra |
| Boston Scientific Corporation | $37.11 | 2025 | General - Therapies |
| Chiesi USA, INC. | $36.76 | 2023-2025 | Cleviprex |
| Argenx US, INC. | $33.70 | 2025 | Vyvgart Hytrulo |
| Lundbeck LLC | $32.43 | 2024 | Vyepti |
| Emd Serono, INC. | $28.99 | 2023 | |
| Amgen INC. | $27.67 | 2024 | |
| Baxter Healthcare | $24.15 | 2023 | Floseal |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immedica Pharma US, INC. | $23.98 | 2024 | |
| Revance Therapeutics, INC. | $20.59 | 2024 | Daxxify |
| Merz Pharmaceuticals, LLC | $19.97 | 2025 | Inbrija, Xeomin |
| Jazz Pharmaceuticals INC. | $17.99 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $15.32 | 2024 | |
| Novartis Pharmaceuticals Corporation | $14.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Oei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.